Afficher la notice abrégée

Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.

dc.rights.licenseopenen_US
dc.contributor.authorLORSCHEIDER, Johannes
dc.contributor.authorSIGNORI, Alessio
dc.contributor.authorSUBRAMANIAM, Suvitha
dc.contributor.authorBENKERT, Pascal
dc.contributor.authorVUKUSIC, Sandra
dc.contributor.authorTROJANO, Maria
dc.contributor.authorHILLERT, Jan
dc.contributor.authorGLASER, Anna
dc.contributor.authorHYDE, Robert
dc.contributor.authorSPELMAN, Tim
dc.contributor.authorMAGYARI, Melinda
dc.contributor.authorELBERLING, Frederik
dc.contributor.authorPONTIERI, Luigi
dc.contributor.authorKOCH-HENRIKSEN, Nils
dc.contributor.authorSØRENSEN, Per Soelberg
dc.contributor.authorGERLACH, Oliver
dc.contributor.authorPRAT, Alexandre
dc.contributor.authorGIRARD, Marc
dc.contributor.authorEICHAU, Sara
dc.contributor.authorGRAMMOND, Pierre
dc.contributor.authorHORAKOVA, Dana
dc.contributor.authorRAMO-TELLO, Cristina
dc.contributor.authorROOS, Izanne
dc.contributor.authorBUZZARD, Katherine
dc.contributor.authorLECHNER SCOTT, Jeanette
dc.contributor.authorSÁNCHEZ-MENOYO, José Luis
dc.contributor.authorALROUGHANI, Raed
dc.contributor.authorPRÉVOST, Julie
dc.contributor.authorKUHLE, Jens
dc.contributor.authorGRAY, Orla
dc.contributor.authorMATHEY, Guillaume
dc.contributor.authorMICHEL, Laure
dc.contributor.authorCIRON, Jonathan
dc.contributor.authorDE SÈZE, Jérôme
dc.contributor.authorMAILLART, Elisabeth
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorRUET, Aurelie
dc.contributor.authorLABAUGE, Pierre
dc.contributor.authorZEPHIR, Helene
dc.contributor.authorKWIATKOWSKI, Arnaud
dc.contributor.authorVAN DER WALT, Anneke
dc.contributor.authorKALINCIK, Tomas
dc.contributor.authorBUTZKUEVEN, Helmut
dc.date.accessioned2025-05-28T07:26:22Z
dc.date.available2025-05-28T07:26:22Z
dc.date.issued2025-05-14
dc.identifier.issn1468-330Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206763
dc.description.abstractEnEffectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains unclear. Our aim was to investigate the potential effect of DMT on disability worsening among patients with PPMS stratified by different disability trajectories. Within the framework of the Big MS Data network, we merged data from the Observatoire Français de la Sclérose en Plaques, the Swedish and Italian MS registries, and MSBase. We identified patients with PPMS that started DMT or were never treated during the observed period. Subpopulations with comparable baseline characteristics were selected by propensity score matching. Disability outcomes were analysed in time-to-recurrent event analyses, which were repeated in subclasses with different disability trajectories determined by latent class mixed models. Of the 3243 included patients, we matched 739 treated and 1330 untreated patients with a median follow-up of 3 years after pairwise censoring. No difference in the risk of confirmed disability worsening (CDW) was observed between the groups in the fully matched dataset (HR 1.11, 95% CI 0.97 to 1.23, p=0.127). However, we found a lower risk for CDW among the class of treated patients with an aggressive disability trajectory (n=360, HR 0.68, 95% CI 0.50 to 0.92, p=0.014). In line with previous studies, our data suggest that DMT does not ameliorate disability worsening in PPMS, in general. However, we observed a beneficial effect of DMT on disability worsening in patients with aggressive predicted disability trajectories.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enHumans
dc.subject.enMultiple Sclerosis
dc.subject.enChronic Progressive
dc.subject.enMale
dc.subject.enFemale
dc.subject.enDisease Progression
dc.subject.enMiddle Aged
dc.subject.enAdult
dc.subject.enRegistries
dc.subject.enDisability Evaluation
dc.subject.enTreatment Outcome
dc.title.enDisease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
dc.title.alternativeJ Neurol Neurosurg Psychiatryen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1136/jnnp-2024-334700en_US
dc.identifier.pubmed39643429en_US
bordeaux.journalJournal of Neurology, Neurosurgery and Psychiatryen_US
bordeaux.page606-615en_US
bordeaux.volume96en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - U1215en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamRelations glie-neuroneen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Neurology,%20Neurosurgery%20and%20Psychiatry&rft.date=2025-05-14&rft.volume=96&rft.issue=6&rft.spage=606-615&rft.epage=606-615&rft.eissn=1468-330X&rft.issn=1468-330X&rft.au=LORSCHEIDER,%20Johannes&SIGNORI,%20Alessio&SUBRAMANIAM,%20Suvitha&BENKERT,%20Pascal&VUKUSIC,%20Sandra&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
MAGENDIE_ JNeurolNeurosurgPsyc ...
Taille:
1.979Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée